Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Capital Expenditures (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Capital Expenditures for 11 consecutive years, with -$1000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 101.16% year-over-year to -$1000.0, compared with a TTM value of $718000.0 through Dec 2025, down 23.45%, and an annual FY2025 reading of $718000.0, down 23.45% over the prior year.
  • Capital Expenditures was -$1000.0 for Q4 2025 at Wave Life Sciences, down from $248000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $492000.0 in Q2 2022 and bottomed at -$1000.0 in Q4 2025.
  • Average Capital Expenditures over 5 years is $234600.0, with a median of $206000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures soared 1260.0% in 2022, then plummeted 101.16% in 2025.
  • Year by year, Capital Expenditures stood at $15000.0 in 2021, then skyrocketed by 1260.0% to $204000.0 in 2022, then soared by 74.51% to $356000.0 in 2023, then tumbled by 75.84% to $86000.0 in 2024, then tumbled by 101.16% to -$1000.0 in 2025.
  • Business Quant data shows Capital Expenditures for WVE at -$1000.0 in Q4 2025, $248000.0 in Q3 2025, and $306000.0 in Q2 2025.